CarlosEduardoArce-LaraMD

Oncology • Casa Grande, AZ

Physician

Join to view full profile

Dr. Arce-Lara is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Arce-Lara's full profile

Already have an account?

Office
1876 E Sabin Dr
Ste 10
Casa Grande, AZ 85122
Phone+1 520-836-9800
Is this information wrong?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2007
University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2005
Mercy Catholic Medical CenterResidency, Internal Medicine, 2001 - 2004
Universidad de Ciencias MedicasClass of 1999

Certifications & Licensure

AZ State Medical License 2018 - 2024
WI State Medical License 2012 - 2019
TX State Medical License 2008 - 2014
OH State Medical License 2005 - 2009
KY State Medical License 2004 - 2006
PA State Medical License 2001 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Start of enrollment: 2017 Oct 17
Completed
Phase 2
Roles: Contact

Publications & Presentations

PubMed

20 citations
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.
Richard F. Ambinder, Juan Wu, Brent R. Logan, Christine M. Durand, Ryan K. Shields, Uday R. Popat, Richard F. Little, Deborah McMahon, Joshua C. Cyktor, John W. Mellor...> ;Biology of Blood and Marrow Transplantation. 2019 Nov 1
13 citations
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
Binod Dhakal, Anita D'Souza, Mehdi Hamadani, Carlos Arce-Lara, Katrina Schroeder, Saurabh Chhabra, Nirav N. Shah, Katelyn Gauger, Taylor Keaton, Marcelo C. Pasquini, P...> ;Blood Cancer Journal. 2019 Jul 29
19 citations
A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative ...
Parameswaran Hari, Omar S. Aljitawi, Carlos Arce-Lara, Rajneesh Nath, Natalie S. Callander, Gajanan Bhat, Lee F. Allen, Keith Stockerl-Goldstein> ;Biology of Blood and Marrow Transplantation. 2015 Dec 1
9 citations
Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis
Amara S. Hussain, Parameswaran Hari, Ruta Brazauskas, Carlos Arce-Lara, Marcelo C. Pasquini, Mehdi Hamadani, Anita D'Souza> ;American Journal of Hematology. 2015 Nov 1
24 citations
Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
Xiaobo Zhong, Carlos Arce-Lara, Ehab Atallah, Linda S. Blust, William R. Drobyski, Timothy S. Fenske, Marcelo C. Pasquini, J D Rizzo, Wael Saber, Parameswaran Hari> ;Bone Marrow Transplantation. 2015 Jul 1
84 citations
Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Adminis...
Rafael Santana-Davila, Kiran Devisetty, Aniko Szabo, Rodney Sparapani, Carlos Arce-Lara, Elizabeth Gore, Amy L. Moran, Christina D. Williams, Michael J. Kelley, Jeff W...> ;Journal of Clinical Oncology. 2015 Feb 20
5 citations
Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis.
Binod Dhakal, Anita D'Souza, Carlos Arce-Lara, Marcelo C. Pasquini, Wael Saber, F Falvo, Jean Esselman, Katie Zellner, Timothy S. Fenske, Parameswaran Hari, Mehdi Hama...> ;Bone Marrow Transplantation. 2015 Jan 26
21 citations
Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis.
Binod Dhakal, Christopher Strouse, Anita D'Souza, Carlos Arce-Lara, Jeanie Esselman, Daniel Eastwood, Marcelo C. Pasquini, Wael Saber, William R. Drobyski, J. Douglas ...> ;Biology of Blood and Marrow Transplantation. 2014 Dec 1
33 citations
Cisplatin versus carboplatin based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data
Rafael Santana-Davila, Aniko Szabo, Carlos Arce-Lara, Christina D. Williams, Michael J. Kelley, Jeff Whittle> ;Journal of Thoracic Oncology. 2014 May 1
3 citations
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials
Nse Ntukidem, Carlos Arce-Lara, Gregory A. Otterson, Eric H. Kraut, Spero R. Cataland, Tanios Bekaii-Saab> ;Cancer Chemotherapy and Pharmacology. 2010 Jan 1
7 citations
Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach.
Carlos Arce-Lara, Manisha H. Shah, Rafael E. Jimenez, Vipul R. Patel, Don M. Benson, Steven K. Clinton, J. Paul Monk> ;Urology. 2007 Jun 1
15 citations
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma
Damian A. Laber, Roseline I. Okeke, Carlos Arce-Lara, B. Taft, Cassandra L. Schonard, Kelly M. McMasters, Goetz H. Kloecker, Donald M. Miller> ;Journal of Cancer Research and Clinical Oncology. 2006 Jun 2
Join now to see all

Lectures

Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018